EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

ALKBH1: emerging biomarker and therapeutic target for cancer treatment

Ming Zhu Xiao, Jin Yin Fu, Le Tao Bo, Yi Dong Li, Zhong Wei Lin, Zhe Sheng Chen

Discover Oncology · 20.12.2024 · 15 (1)

DOI: 10.1007/s12672-024-01696-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Discover Oncology, online erschienen am 20.12.2024. Verfasst von Ming Zhu Xiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pharmaceutical Bioactive Substances, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: 2020 Science and Technology Special Commissioner Fund of Guangdong Science and Technology Department, Natural Science Foundation of Guangdong Province, 2023 International Training Program for Outstanding Young Scientific Research Talents of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As neoplastic cells proliferate, disseminate, and infiltrate, they undergo substantial alterations in their epigenetic configuration. Among the pivotal enzymes implicated in this phenomenon is the AlkB family of demethylases, notably AlkB homolog 1 (ALKBH1), which demonstrates conspicuous upregulation across various malignancies. The heightened expression of ALKBH1 renders it a compelling candidate for the development of multifaceted anticancer modalities. Despite the commendable progress achieved by investigators in elucidating the perturbations associated with ALKBH1 in malignant tissues, a comprehensive mechanism remains elusive. The present study endeavors to address this lacuna by synthesizing recent advancements pertaining to ALKBH1's involvement in oncogenesis over the preceding decade. Therefore, this research not only furnishes novel insights but also establishes a foundation for prospective initiatives aimed at cancer prophylaxis and therapeutics that exploit epigenetic regulatory mechanisms.

Schlagwörter

Stichwörter der Autor:innen

ALKBH1CancerDNA/RNAMethylation and demethylation

Autor:innen und Institutionen

  • Key Laboratory of Pharmaceutical Bioactive Substances, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
  • Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA. chenz@stjohns.edu.

Förderung

  • 2020 Science and Technology Special Commissioner Fund of Guangdong Science and Technology Department
  • Natural Science Foundation of Guangdong Province
  • 2023 International Training Program for Outstanding Young Scientific Research Talents of Guangdong Province

Zitieren

APA

Xiao, M. Z., Fu, J. Y., Bo, L. T., Li, Y. D., Lin, Z. W., & Chen, Z. S. (2024). ALKBH1: emerging biomarker and therapeutic target for cancer treatment. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-01696-5

Vancouver

Xiao MZ, Fu JY, Bo LT, Li YD, Lin ZW, Chen ZS. ALKBH1: emerging biomarker and therapeutic target for cancer treatment. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-01696-5

BibTeX
@article{Xiao2024,
  author = {Xiao, Ming Zhu and Fu, Jin Yin and Bo, Le Tao and Li, Yi Dong and Lin, Zhong Wei and Chen, Zhe Sheng},
  title = {ALKBH1: emerging biomarker and therapeutic target for cancer treatment},
  journal = {Discover Oncology},
  year = {2024},
  volume = {15},
  number = {1},
  doi = {10.1007/s12672-024-01696-5}
}
Kostenlos starten →